Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MDM4 | O15151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 3/20 | 0.49 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31180735 | 1.00 | MDM2 (0.55) | MDM2KMT2AMDM4TP53IDO1 | |
| SCHEMBL29400825 | 1.00 | MDM2 (0.55) | MDM2KMT2AMDM4TP53IDO1 | |
| SCHEMBL29594390 | 1.00 | MDM2 (0.55) | MDM2KMT2AMDM4TP53IDO1 | |
| SCHEMBL1000910 | 1.00 | MDM2 (0.55) | MDM2KMT2AMDM4TP53IDO1 | |
| SCHEMBL29362665 | 0.96 | MDM2 (0.57) | MDM2KMT2AMDM4TP53TLR2 | |
| SCHEMBL14039221 | 0.96 | MDM2 (0.57) | MDM2KMT2AMDM4TP53TLR2 | |
| SCHEMBL30385460 | 0.96 | MDM2 (0.57) | MDM2KMT2AMDM4TP53TLR2 | |
| SCHEMBL29383813 | 0.96 | MDM2 (0.57) | MDM2KMT2AMDM4TP53TLR2 | |
| SCHEMBL30645673 | 0.96 | MDM2 (0.57) | MDM2KMT2AMDM4TP53TLR2 | |
| SCHEMBL4612515 | 0.96 | MDM2 (0.57) | MDM2KMT2AMDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310330-A1 | PEPTIDIC OLIGOMERS AND METHODS OF USING THE SAME | BIOVENTURES LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-11674136-B2 | DNA-templated macrocycle library | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-13 | — | — | US | disclosed |
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200399634-A1 | DNA-TEMPLATED MACROCYCLE LIBRARY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-12-24 | — | — | US | disclosed |
| EP-3700545-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | Southern Research Institute (US) | 2020-09-02 | — | — | EP | disclosed |
| WO-2019168654-A9 | DNA-TEMPLATED MACROCYCLE LIBRARY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION | 2019-05-02 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| EP-2519664-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | Avila Therapeutics, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| WO-2011082285-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | AVILA THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| CN-101951769-A | Hcv protease inhibitors and uses thereof | AVILA THERAPEUTICS INC | 2011-01-19 | — | — | CN | disclosed |
| US-7863455-B2 | Electrochemically active ligand for sequence-specific detection of double-stranded nucleic acid molecule | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-01-04 | — | — | US | disclosed |
| US-20070172826-A1 | Electrochemically active ligand for sequence-specific detection of double-stranded nucleic acid molecule | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1719777-A1 | ELECTROCHEMICALLY ACTIVE LIGAND FOR SEQUENCE-SPECIFIC DETECTION OF DOUBLE-STRANDED NUCLEIC ACID MOLECULE | Japan Science and Technology Agency (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11674136-B2 | DNA-templated macrocycle library | IDE, IAPP, POLRMT | MDM2 938/4885KMT2A 3958/4885MDM4 1827/4885 |
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | MDM2 72/4885KMT2A 1160/4885MDM4 1746/4885 |
| US-20070172826-A1 | Electrochemically active ligand for sequence-specific detection of double-stranded nucleic acid molecule | POLRMT, POLM, POLI | MDM2 4548/4885KMT2A 440/4885MDM4 3810/4885 |
| US-20200399634-A1 | DNA-TEMPLATED MACROCYCLE LIBRARY | IDE, IAPP, POLRMT | MDM2 938/4885KMT2A 3958/4885MDM4 1827/4885 |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | PTMS, SPR, DNPEP | MDM2 72/4885KMT2A 1160/4885MDM4 1746/4885 |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | TGFB1, TGFB2, SMAD3 | MDM2 993/4885KMT2A 1644/4885MDM4 1715/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | MDM2 72/4885KMT2A 1160/4885MDM4 1746/4885 |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | TGFB1, TGFB2, SMAD3 | MDM2 993/4885KMT2A 1644/4885MDM4 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.